Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01335464




Registration number
NCT01335464
Ethics application status
Date submitted
13/04/2011
Date registered
14/04/2011
Date last updated
25/07/2016

Titles & IDs
Public title
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Scientific title
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Secondary ID [1] 0 0
2010-024251-87
Secondary ID [2] 0 0
1199.32
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - placebo
Treatment: Drugs - BIBF 1120

Experimental: BIBF 1120 - patient receives capsules containing BIBF 1120 twice a day

Placebo Comparator: placebo - patient receives capsules identical to those containing active drug


Treatment: Drugs: placebo
placebo matching BIBF1120, BID

Treatment: Drugs: BIBF 1120
BIBF1120 BID (twice daily)

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks - Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.
For this endpoint reported means represent the adjusted rate
Timepoint [1] 0 0
52 weeks
Secondary outcome [1] 0 0
Change From Baseline in Saint-George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks - This is a key secondary endpoint.
SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.
The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.
Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Timepoint [1] 0 0
baseline and 52 weeks
Secondary outcome [2] 0 0
Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation - Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows:
Otherwise unexplained clinical features including all of the following:
Unexplained worsening or development of dyspnoea within 30 days
New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit
Exclusion of infection as per routine clinical practice and microbiological studies
Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.
Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .
Timepoint [2] 0 0
52 weeks
Secondary outcome [3] 0 0
Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks - Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Timepoint [3] 0 0
Baseline and 52 weeks
Secondary outcome [4] 0 0
Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks - Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Timepoint [4] 0 0
Baseline and 52 weeks
Secondary outcome [5] 0 0
Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks - Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Timepoint [5] 0 0
Baseline and 52 weeks
Secondary outcome [6] 0 0
Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks - Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Timepoint [6] 0 0
Baseline and 52 weeks
Secondary outcome [7] 0 0
Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold - Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by >5%, increase by >5%, and change within =5%).
Timepoint [7] 0 0
Baseline and 52 weeks
Secondary outcome [8] 0 0
Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold - Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by >10%, and change within =10%)
Timepoint [8] 0 0
Baseline and 52 weeks
Secondary outcome [9] 0 0
FVC Responders Using 10% Threshold at 52 Weeks - FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.
Timepoint [9] 0 0
52 weeks
Secondary outcome [10] 0 0
Proportion of FVC Responders Using 5% Threshold at 52 Weeks - Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.
Timepoint [10] 0 0
52 weeks
Secondary outcome [11] 0 0
Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs) - Proportion of SGRQ responders at 52 weeks
Responders defined as <= -4 points change in change from baseline in SGRQ total score at 52 weeks.
Timepoint [11] 0 0
Baseline and 52 weeks
Secondary outcome [12] 0 0
Change From Baseline in SGRQ Symptom Score at 52 Weeks: Patient Reported Outcomes (PROs) - SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Timepoint [12] 0 0
Baseline and 52 weeks
Secondary outcome [13] 0 0
Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs) - SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Timepoint [13] 0 0
Baseline and 52 weeks
Secondary outcome [14] 0 0
Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs) - SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Timepoint [14] 0 0
baseline and 52 weeks
Secondary outcome [15] 0 0
Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs) - SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.
The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.
Timepoint [15] 0 0
Baseline and 52 weeks
Secondary outcome [16] 0 0
Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs) - Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Timepoint [16] 0 0
baseline and 52 weeks
Secondary outcome [17] 0 0
Change From Baseline in Cough Symptoms Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs) - The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Timepoint [17] 0 0
Baseline and 52 weeks
Secondary outcome [18] 0 0
Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks : Patient Reported Outcomes (PROs) - The cough domains of the Cough and Sputum Assessment Questionnaire (CASA-Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Timepoint [18] 0 0
Baseline and 52 weeks
Secondary outcome [19] 0 0
Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs) - Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.
Timepoint [19] 0 0
52 weeks
Secondary outcome [20] 0 0
Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs) - The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.
Timepoint [20] 0 0
baseline, 12 weeks, 24 weeks and 52 weeks
Secondary outcome [21] 0 0
Risk of an Acute IPF Exacerbation Over 52 Weeks - The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years*100)
Timepoint [21] 0 0
52 weeks
Secondary outcome [22] 0 0
Time to Death Over 52 Weeks - Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died over 52 weeks (373 days time-period) .
Timepoint [22] 0 0
52 weeks
Secondary outcome [23] 0 0
Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated) - Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).
Timepoint [23] 0 0
52 weeks
Secondary outcome [24] 0 0
Time to On-treatment Death - Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported.
Failure is the the proportion of patients who died on-treatment.
Timepoint [24] 0 0
52 weeks
Secondary outcome [25] 0 0
Time to Death or Lung Transplant Over 52 Weeks - Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).
Timepoint [25] 0 0
52 weeks
Secondary outcome [26] 0 0
Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks. - Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:
FVC <45% predicted or Carbon monoxide diffusion capacity (DL(CO)) <30% pred or Oxygen saturation on pulse oximetry (SpO2) <88% at rest, at sea level (to be adapted for other heights).
These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).
Timepoint [26] 0 0
52 weeks
Secondary outcome [27] 0 0
Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks - Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)
Timepoint [27] 0 0
Baseline and 52 weeks
Secondary outcome [28] 0 0
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks - Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Timepoint [28] 0 0
Baseline and 52 weeks

Eligibility
Key inclusion criteria
Inclusion criteria:

1. Age >= 40 years;

2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European
Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic
Association (ALAT) IPF guideline for diagnosis and management, within 5 years;

3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if
available surgical lung biopsy pattern, as assessed by central reviewers, are
consistent with diagnosis of IPF

4. Dlco (corrected for Hb): 30%-79% predicted of normal;

5. FVC>= 50% predicted of normal
Minimum age
40 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit
of Normal (ULN)

2. Bilirubin > 1.5 x ULN;

3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);

4. Patient likely to have lung transplantation during study (being on transplantation
list is acceptable for participation);

5. Myocardial infarction within 6 months;

6. Unstable angina within 1 month;

7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic
anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event
within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or
ulcers or major injury or surgery within 3 months);

8. Thrombotic risk (inherited predisposition; history of thrombotic event (including
stroke and transient ischemic attacks) within 12 months;

9. International normalised ratio (INR) > 2, prolongation of prothrombin time (PT) and
partial thromboplastin time (PTT) by > 50% of institutional ULN);

10. N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit
1;

11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of
visit 1;

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
1199.32.61001 Boehringer Ingelheim Investigational Site - Camperdown
Recruitment hospital [2] 0 0
1199.32.61002 Boehringer Ingelheim Investigational Site - Concord
Recruitment hospital [3] 0 0
1199.32.61003 Boehringer Ingelheim Investigational Site - Daw Park
Recruitment hospital [4] 0 0
1199.32.61005 Boehringer Ingelheim Investigational Site - Frankston
Recruitment hospital [5] 0 0
1199.32.61004 Boehringer Ingelheim Investigational Site - Prahran
Recruitment postcode(s) [1] 0 0
- Camperdown
Recruitment postcode(s) [2] 0 0
- Concord
Recruitment postcode(s) [3] 0 0
- Daw Park
Recruitment postcode(s) [4] 0 0
- Frankston
Recruitment postcode(s) [5] 0 0
- Prahran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Delaware
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Rhode Island
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Belgium
State/province [20] 0 0
Bruxelles
Country [21] 0 0
Belgium
State/province [21] 0 0
Jette
Country [22] 0 0
Belgium
State/province [22] 0 0
Leuven
Country [23] 0 0
Belgium
State/province [23] 0 0
Yvoir
Country [24] 0 0
China
State/province [24] 0 0
Beijing
Country [25] 0 0
China
State/province [25] 0 0
Changsha
Country [26] 0 0
China
State/province [26] 0 0
Chengdu
Country [27] 0 0
China
State/province [27] 0 0
Nanchang
Country [28] 0 0
China
State/province [28] 0 0
Xi'An
Country [29] 0 0
Czech Republic
State/province [29] 0 0
Prague 4
Country [30] 0 0
Czech Republic
State/province [30] 0 0
Prague 8
Country [31] 0 0
Czech Republic
State/province [31] 0 0
Usti nad Labem
Country [32] 0 0
France
State/province [32] 0 0
Bobigny
Country [33] 0 0
France
State/province [33] 0 0
Nice Cedex 1
Country [34] 0 0
France
State/province [34] 0 0
Paris Cedex 15
Country [35] 0 0
France
State/province [35] 0 0
Paris Cedex 18
Country [36] 0 0
France
State/province [36] 0 0
Paris cedex 20
Country [37] 0 0
France
State/province [37] 0 0
Reims cedex
Country [38] 0 0
France
State/province [38] 0 0
Rennes Cedex 9
Country [39] 0 0
Germany
State/province [39] 0 0
Bamberg
Country [40] 0 0
Germany
State/province [40] 0 0
Donaustauf
Country [41] 0 0
Germany
State/province [41] 0 0
Essen
Country [42] 0 0
Germany
State/province [42] 0 0
Freiburg/Breisgau
Country [43] 0 0
Germany
State/province [43] 0 0
Gießen
Country [44] 0 0
Germany
State/province [44] 0 0
Großhansdorf
Country [45] 0 0
Germany
State/province [45] 0 0
Heidelberg
Country [46] 0 0
Germany
State/province [46] 0 0
Mainz
Country [47] 0 0
India
State/province [47] 0 0
Ahmedabad
Country [48] 0 0
India
State/province [48] 0 0
Coimbatore
Country [49] 0 0
India
State/province [49] 0 0
Jaipur
Country [50] 0 0
India
State/province [50] 0 0
Kolkatta
Country [51] 0 0
India
State/province [51] 0 0
Mumbai
Country [52] 0 0
Ireland
State/province [52] 0 0
Dublin
Country [53] 0 0
Israel
State/province [53] 0 0
Haifa
Country [54] 0 0
Israel
State/province [54] 0 0
Petah Tiqwa
Country [55] 0 0
Israel
State/province [55] 0 0
Rehovot
Country [56] 0 0
Italy
State/province [56] 0 0
Catania
Country [57] 0 0
Italy
State/province [57] 0 0
Chieti Scalo
Country [58] 0 0
Italy
State/province [58] 0 0
Forli'
Country [59] 0 0
Italy
State/province [59] 0 0
Milano
Country [60] 0 0
Italy
State/province [60] 0 0
Modena
Country [61] 0 0
Italy
State/province [61] 0 0
Monza
Country [62] 0 0
Italy
State/province [62] 0 0
Napoli
Country [63] 0 0
Italy
State/province [63] 0 0
Padova
Country [64] 0 0
Italy
State/province [64] 0 0
Pisa
Country [65] 0 0
Italy
State/province [65] 0 0
Roma
Country [66] 0 0
Italy
State/province [66] 0 0
Siena
Country [67] 0 0
Japan
State/province [67] 0 0
Bunkyo-ku,Tokyo
Country [68] 0 0
Japan
State/province [68] 0 0
Kiyose, Tokyo
Country [69] 0 0
Japan
State/province [69] 0 0
Kumagaya, Saitama
Country [70] 0 0
Japan
State/province [70] 0 0
Minato-ku, Tokyo
Country [71] 0 0
Japan
State/province [71] 0 0
Naka-gun, Ibaraki
Country [72] 0 0
Japan
State/province [72] 0 0
Ota-ku, Tokyo
Country [73] 0 0
Japan
State/province [73] 0 0
Sendai, Miyagi
Country [74] 0 0
Japan
State/province [74] 0 0
Shibuya-ku, Tokyo
Country [75] 0 0
Japan
State/province [75] 0 0
Shimotsuke,Tochigi
Country [76] 0 0
Japan
State/province [76] 0 0
Shinjuku-ku, Tokyo
Country [77] 0 0
Japan
State/province [77] 0 0
Yokohama, Kanagawa
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Aberdeen
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Birmingham
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Leeds
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Liverpool
Country [82] 0 0
United Kingdom
State/province [82] 0 0
London
Country [83] 0 0
United Kingdom
State/province [83] 0 0
Oxford
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Westbury on Trym

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in
scarring of the lung and there is a high unmet medical need for effective treatment to halt
lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the
death rate.

In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of
treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of
patients treated with high dose of BIBF 1120 compared to placebo.

Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of
BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will
be conducted as a prospective, randomised design with the aim to collect safety and efficacy
data.

Respiratory function is globally accepted for assessment of treatment effects in IPF
patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is
part of the usual examinations done in IPF patients.
Trial website
https://clinicaltrials.gov/show/NCT01335464
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications